This narrative review discusses the potential role of osimertinib for patients with non-small cell lung cancer who have EGFR mutations and have become resistant to earlier EGFR-TKI treatments. The study did not report a specific sample size or follow-up period, as it is a review of existing information rather than a new clinical trial.
The authors explore how this medication might be used in this specific population. No primary or secondary outcomes were reported in the provided data, and no specific safety concerns, adverse events, or discontinuations were detailed in this summary.
Because this is a narrative review and not a practice-changing study with reported results, readers should understand that the evidence is limited. The findings are based on existing literature and may not represent definitive proof of benefit or safety for all patients. More research is needed to determine the best use of this drug in this setting.
